FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297408> ?p ?o ?g. }

• W4286297408 endingPage "3114" @default.
• W4286297408 startingPage "3114" @default.
• W4286297408 abstract "3114 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of solid tumor pts with mTOR mutation (mut) treated with T are reported. Methods: Eligible pts had solid tumors, no standard treatment (tx) options, measurable disease, ECOG Performance Status (PS) 0-2, and adequate organ function. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts matched to T had various solid tumors with mTOR mut. After antihistamine pre-treatment, 25 mg T was infused over 30-60 minutes weekly until disease progression. Primary endpoint was disease control (DC), defined as complete (CR) or partial (PR) response, or stable disease at 16+ weeks (wks) (SD 16+) (RECIST v1.1). Low accruing histology-specific cohorts with the same genomic alteration and tx were collapsed into a single histology-pooled cohort for this analysis. For histology-pooled cohorts with sample size ≤28, the results are evaluated based on a one-sided exact binomial test with a null DC rate of 15% vs. 35% (α = 0.10 and power=0.86 for N = 26) and one-sided 90% confidence interval (CI). Other efficacy endpoint estimates are presented with two-sided 95% CIs. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Results: 29 pts with solid tumors (11 histologies) with mTOR mut were enrolled from June 2016 to June 2020. 3 pts were not evaluable (2 pts, no post-baseline tumor eval; 1 pt, no measurable disease) and excluded from efficacy analyses. The Table shows demographics and outcomes. 2 PR and 10 SD16+ were observed for a DC rate of 46% (one-sided 90% CI: 32% to 100%) and an objective response (OR) rate of 8% (95% CI: 1% to 25%); the null hypothesis of a 15% DC rate is rejected (p<0.001). 5/10 pts with SD16+ had CRC or biliary cancer. Of the 2 pts with PR, one had uterine cancer and T1977R mut and the other had head and neck cancer and I1636V mut. The durations of PR were 12.3 and 23.9 wks, respectively, and median duration of SD was 34.5 wks (range: 18.7, 90.0) for pts with SD16+. 8 pts experienced grade 3 or grade 4 AEs or SAEs at least possibly related to T, including acute kidney injury, epistaxis, hyperglycemia, hypertension, hypertriglyceridemia, mucositis, leukopenia, thrombocytopenia, and pneumonitis. Conclusions: Monotherapy T showed evidence of anti-tumor activity in pts with advanced solid tumors with mTOR mut. Additional study is warranted to confirm the efficacy of T in pts with mTOR mut. Clinical trial information: NCT02693535. [Table: see text]" @default.
• W4286297408 created "2022-07-21" @default.
• W4286297408 creator A5011966384 @default.
• W4286297408 creator A5031299191 @default.
• W4286297408 creator A5032230772 @default.
• W4286297408 creator A5034428260 @default.
• W4286297408 creator A5038911499 @default.
• W4286297408 creator A5041306590 @default.
• W4286297408 creator A5044876102 @default.
• W4286297408 creator A5047690131 @default.
• W4286297408 creator A5052563056 @default.
• W4286297408 creator A5053172275 @default.
• W4286297408 creator A5058562764 @default.
• W4286297408 creator A5068387334 @default.
• W4286297408 creator A5070120524 @default.
• W4286297408 creator A5073432388 @default.
• W4286297408 creator A5074206468 @default.
• W4286297408 creator A5078986413 @default.
• W4286297408 creator A5080066618 @default.
• W4286297408 creator A5081600691 @default.
• W4286297408 creator A5084766986 @default.
• W4286297408 date "2022-06-01" @default.
• W4286297408 modified "2023-09-29" @default.
• W4286297408 title "Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study." @default.
• W4286297408 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3114" @default.
• W4286297408 hasPublicationYear "2022" @default.
• W4286297408 type Work @default.
• W4286297408 citedByCount "1" @default.
• W4286297408 countsByYear W42862974082023 @default.
• W4286297408 crossrefType "journal-article" @default.
• W4286297408 hasAuthorship W4286297408A5011966384 @default.
• W4286297408 hasAuthorship W4286297408A5031299191 @default.
• W4286297408 hasAuthorship W4286297408A5032230772 @default.
• W4286297408 hasAuthorship W4286297408A5034428260 @default.
• W4286297408 hasAuthorship W4286297408A5038911499 @default.
• W4286297408 hasAuthorship W4286297408A5041306590 @default.
• W4286297408 hasAuthorship W4286297408A5044876102 @default.
• W4286297408 hasAuthorship W4286297408A5047690131 @default.
• W4286297408 hasAuthorship W4286297408A5052563056 @default.
• W4286297408 hasAuthorship W4286297408A5053172275 @default.
• W4286297408 hasAuthorship W4286297408A5058562764 @default.
• W4286297408 hasAuthorship W4286297408A5068387334 @default.
• W4286297408 hasAuthorship W4286297408A5070120524 @default.
• W4286297408 hasAuthorship W4286297408A5073432388 @default.
• W4286297408 hasAuthorship W4286297408A5074206468 @default.
• W4286297408 hasAuthorship W4286297408A5078986413 @default.
• W4286297408 hasAuthorship W4286297408A5080066618 @default.
• W4286297408 hasAuthorship W4286297408A5081600691 @default.
• W4286297408 hasAuthorship W4286297408A5084766986 @default.
• W4286297408 hasConcept C126322002 @default.
• W4286297408 hasConcept C141071460 @default.
• W4286297408 hasConcept C143998085 @default.
• W4286297408 hasConcept C183713625 @default.
• W4286297408 hasConcept C185592680 @default.
• W4286297408 hasConcept C190283241 @default.
• W4286297408 hasConcept C203092338 @default.
• W4286297408 hasConcept C207103383 @default.
• W4286297408 hasConcept C2776820818 @default.
• W4286297408 hasConcept C44249647 @default.
• W4286297408 hasConcept C535046627 @default.
• W4286297408 hasConcept C55493867 @default.
• W4286297408 hasConcept C57742111 @default.
• W4286297408 hasConcept C71924100 @default.
• W4286297408 hasConcept C72563966 @default.
• W4286297408 hasConcept C86554907 @default.
• W4286297408 hasConceptScore W4286297408C126322002 @default.
• W4286297408 hasConceptScore W4286297408C141071460 @default.
• W4286297408 hasConceptScore W4286297408C143998085 @default.
• W4286297408 hasConceptScore W4286297408C183713625 @default.
• W4286297408 hasConceptScore W4286297408C185592680 @default.
• W4286297408 hasConceptScore W4286297408C190283241 @default.
• W4286297408 hasConceptScore W4286297408C203092338 @default.
• W4286297408 hasConceptScore W4286297408C207103383 @default.
• W4286297408 hasConceptScore W4286297408C2776820818 @default.
• W4286297408 hasConceptScore W4286297408C44249647 @default.
• W4286297408 hasConceptScore W4286297408C535046627 @default.
• W4286297408 hasConceptScore W4286297408C55493867 @default.
• W4286297408 hasConceptScore W4286297408C57742111 @default.
• W4286297408 hasConceptScore W4286297408C71924100 @default.
• W4286297408 hasConceptScore W4286297408C72563966 @default.
• W4286297408 hasConceptScore W4286297408C86554907 @default.
• W4286297408 hasFunder F4320307765 @default.
• W4286297408 hasIssue "16_suppl" @default.
• W4286297408 hasLocation W42862974081 @default.
• W4286297408 hasOpenAccess W4286297408 @default.
• W4286297408 hasPrimaryLocation W42862974081 @default.
• W4286297408 hasRelatedWork W1516595110 @default.
• W4286297408 hasRelatedWork W1900595920 @default.
• W4286297408 hasRelatedWork W2114624491 @default.
• W4286297408 hasRelatedWork W2194631636 @default.
• W4286297408 hasRelatedWork W2490521022 @default.
• W4286297408 hasRelatedWork W2561875242 @default.
• W4286297408 hasRelatedWork W2809220925 @default.
• W4286297408 hasRelatedWork W2905790652 @default.
• W4286297408 hasRelatedWork W3111094672 @default.
• W4286297408 hasRelatedWork W4224039515 @default.
• W4286297408 hasVolume "40" @default.
• W4286297408 isParatext "false" @default.

• next